These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

222 related items for PubMed ID: 35013835

  • 1. Performance Evaluation of Montelukast Pediatric Formulations: Part I-Age-Related In Vitro Conditions.
    Guimarães M, Somville P, Vertzoni M, Fotaki N.
    AAPS J; 2022 Jan 10; 24(1):26. PubMed ID: 35013835
    [Abstract] [Full Text] [Related]

  • 2. Performance Evaluation of Montelukast Pediatric Formulations: Part II - a PBPK Modelling Approach.
    Guimarães M, Vertzoni M, Fotaki N.
    AAPS J; 2022 Jan 10; 24(1):27. PubMed ID: 35013803
    [Abstract] [Full Text] [Related]

  • 3. In Vivo Predictive Dissolution Testing of Montelukast Sodium Formulations Administered with Drinks and Soft Foods to Infants.
    Martir J, Flanagan T, Mann J, Fotaki N.
    AAPS PharmSciTech; 2020 Oct 13; 21(7):282. PubMed ID: 33051713
    [Abstract] [Full Text] [Related]

  • 4. Impact of Food and Drink Administration Vehicles on Paediatric Formulation Performance Part 2: Dissolution of Montelukast Sodium and Mesalazine Formulations.
    Martir J, Flanagan T, Mann J, Fotaki N.
    AAPS PharmSciTech; 2020 Oct 15; 21(7):287. PubMed ID: 33063245
    [Abstract] [Full Text] [Related]

  • 5. Preparation and In Vitro Evaluation of Montelukast Sodium-Loaded 3D Printed Orodispersible Films for the Treatment of Asthma.
    Özcan-Bülbül E, Kalender Y, Bal-Öztürk A, Üstündağ-Okur N.
    AAPS PharmSciTech; 2024 Sep 17; 25(7):218. PubMed ID: 39289238
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Potential prediction of formulation performance in paediatric patients using biopharmaceutical tools and simulation of clinically relevant administration scenarios of nifedipine and lorazepam.
    Van der Vossen AC, Hanff LM, Vulto AG, Fotaki N.
    Br J Clin Pharmacol; 2019 Aug 17; 85(8):1728-1739. PubMed ID: 30964947
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. In vitro biorelevant models for evaluating modified release mesalamine products to forecast the effect of formulation and meal intake on drug release.
    Andreas CJ, Chen YC, Markopoulos C, Reppas C, Dressman J.
    Eur J Pharm Biopharm; 2015 Nov 17; 97(Pt A):39-50. PubMed ID: 26391972
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Dynamic dissolution testing to establish in vitro/in vivo correlations for montelukast sodium, a poorly soluble drug.
    Okumu A, DiMaso M, Löbenberg R.
    Pharm Res; 2008 Dec 17; 25(12):2778-85. PubMed ID: 18560996
    [Abstract] [Full Text] [Related]

  • 13. Prediction of the Oral Pharmacokinetics and Food Effects of Gabapentin Enacarbil Extended-Release Tablets Using Biorelevant Dissolution Tests.
    Yamaguchi Ikeuchi S, Kambayashi A, Kojima H, Oku N, Asai T.
    Biol Pharm Bull; 2018 Dec 17; 41(11):1708-1715. PubMed ID: 30381671
    [Abstract] [Full Text] [Related]

  • 14. Pilot Study of Peak Plasma Concentration After High-Dose Oral Montelukast in Children With Acute Asthma Exacerbations.
    Arnold DH, Van Driest SL, Reiss TF, King JC, Akers WS.
    J Clin Pharmacol; 2021 Mar 17; 61(3):360-367. PubMed ID: 32960980
    [Abstract] [Full Text] [Related]

  • 15. Validation of Dissolution Testing with Biorelevant Media: An OrBiTo Study.
    Mann J, Dressman J, Rosenblatt K, Ashworth L, Muenster U, Frank K, Hutchins P, Williams J, Klumpp L, Wielockx K, Berben P, Augustijns P, Holm R, Hofmann M, Patel S, Beato S, Ojala K, Tomaszewska I, Bruel JL, Butler J.
    Mol Pharm; 2017 Dec 04; 14(12):4192-4201. PubMed ID: 28737403
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Evaluating Solubility of Celecoxib in Age-Appropriate Fasted- and Fed-State Gastric and Intestinal Biorelevant Media Representative of Adult and Pediatric Patients: Implications on Future Pediatric Biopharmaceutical Classification System.
    Shawahna R, Zyoud A, Haj-Yahia A, Taya R.
    AAPS PharmSciTech; 2021 Mar 01; 22(3):84. PubMed ID: 33649887
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Oral biopharmaceutics tools: recent progress from partnership through the Pharmaceutical Education and Research with Regulatory Links collaboration.
    O'Dwyer PJ, Box KJ, Dressman J, Griffin BT, Henze LJ, Litou C, Pentafragka C, Statelova M, Vertzoni M, Reppas C.
    J Pharm Pharmacol; 2021 Mar 08; 73(4):437-446. PubMed ID: 33793836
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.